The profile of heparanase expression distinguishes differentiated thyroid carcinoma from benign neoplasms

PLoS ONE

Volumn 10, Issue 10, 2015, Pages

  Matos, Leandro Luongo ^a,b   Suarez, Eloah Rabello ^a,b   Theodoro, Thérèse Rachell ^a   Trufelli, Damila Cristina ^a   Melo, Carina Mucciolo ^b   Garcia, Larissa Ferraz ^a   Oliveira, Olivia Capela Grimaldi ^c   Matos, Maria Graciela Luongo ^d   Kanda, Jossi Ledo ^a   Nader, Helena Bonciani ^b   Martins, João Roberto Maciel ^b   Pinhal, Maria Aparecida Silva ^a,b  

^a FACULDADE DE MEDICINA DO ABC   (Brazil)

^b FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^c Necropsy Sector   (Brazil)

^d MASTERS AND DOCTORAL PROGRAMS IN PHYSICAL THERAPY   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

HEPARANASE; HEPARANASE 2; MESSENGER RNA; UNCLASSIFIED DRUG; BETA GLUCURONIDASE;

ADULT; ARTICLE; CANCER CELL; CARCINOGENESIS; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; DIAGNOSTIC TEST ACCURACY STUDY; DIFFERENTIAL DIAGNOSIS; DIFFERENTIATED THYROID CANCER; ENZYMATIC ASSAY; ENZYME ACTIVITY; FEMALE; HASHIMOTO DISEASE; HUMAN; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; MALE; PREDICTIVE VALUE; PROSPECTIVE STUDY; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; THYROID ADENOMA; THYROID FOLLICULAR CARCINOMA; THYROID NODULE; THYROID PAPILLARY CARCINOMA; THYROID TUMOR; WESTERN BLOTTING; METABOLISM; MIDDLE AGED; NEOPLASM; PATHOLOGY; PROCEDURES; THYROID GLAND;

DIAGNOSIS, DIFFERENTIAL; FEMALE; GLUCURONIDASE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOPLASMS; THYROID GLAND; THYROID NEOPLASMS;

EID: 84949501820     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0141139     Document Type: Article

References (46)

1. Yassa L, Cibas ES, Benson CB, Frates MC, Doubilet PM, Gawande AA, et al. Long-term assessment of a multidisciplinary approach to thyroid nodule diagnostic evaluation. Cancer. 2007; 111(6):508-16. Epub 2007/11/14. doi: 10.1002/cncr.23116 PMID: 17999413.
2. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009; 19(11):1167-214. Epub 2009/10/29. doi: 10.1089/thy.2009.0110 PMID: 19860577.
3. Wang CC, Friedman L, Kennedy GC, Wang H, Kebebew E, Steward DL, et al. A large multicenter correlation study of thyroid nodule cytopathology and histopathology. Thyroid. 2011; 21(3):243-51. Epub 2010/12/31. doi: 10.1089/thy.2010.0243 PMID: 21190442.
4. Hodak SP, Rosenthal DS. Information for clinicians: commercially available molecular diagnosis testing in the evaluation of thyroid nodule fine-needle aspiration specimens. Thyroid. 2013; 23(2):131-4. Epub 2012/09/19. doi: 10.1089/thy.2012.0320 PMID: 22984796.
5. Brown LM, Helmke SM, Hunsucker SW, Netea-Maier RT, Chiang SA, Heinz DE, et al. Quantitative and qualitative differences in protein expression between papillary thyroid carcinoma and normal thyroid tissue. Molecular carcinogenesis. 2006; 45(8):613-26. doi: 10.1002/mc.20193 PMID: 16788983; PubMed Central PMCID: PMC1899163.
6. Myers MB, McKim KL, Parsons BL. A subset of papillary thyroid carcinomas contain KRAS mutant subpopulations at levels above normal thyroid. Molecular carcinogenesis. 2014; 53(2):159-67. doi: 10.1002/mc.21953 PMID: 22930660.
7. Matos LL, Del Giglio AB, Matsubayashi CO, Farah ML, Del Giglio A, Pinhal MA. Expression of ck-19, galectin-3 and hbme-1 in the differentiation of thyroid lesions: systematic review and diagnostic metaanalysis. Diagn Pathol. 2012; 7(1):97. Epub 2012/08/15. doi: 1746-1596-7-97 [pii] doi: 10.1186/1746-1596-7-97 PMID: 22888980.
8. Saggiorato E, De Pompa R, Volante M, Cappia S, Arecco F, Dei Tos AP, et al. Characterization of thyroid 'follicular neoplasms' in fine-needle aspiration cytological specimens using a panel of immunohistochemical markers: a proposal for clinical application. Endocr Relat Cancer. 2005; 12(2):305-17. Epub 2005/06/11. doi: 12/2/305 [pii] doi: 10.1677/erc.1.00944 PMID: 15947105.
9. McAllister SS, Weinberg RA. Tumor-host interactions: a far-reaching relationship. J Clin Oncol. 2010; 28(26):4022-8. Epub 2010/07/21. doi: 10.1200/JCO.2010.28.4257 JCO.2010.28.4257 [pii]. PMID: 20644094.
10. Ilan N, Elkin M, Vlodavsky I. Regulation, function and clinical significance of heparanase in cancer metastasis and angiogenesis. Int J Biochem Cell Biol. 2006; 38(12):2018-39. Epub 2006/08/12. doi: S1357-2725(06)00191-9 [pii] doi: 10.1016/j.biocel.2006.06.004 PMID: 16901744.
11. Vlodavsky I, Elkin M, Abboud-Jarrous G, Levi-Adam F, Fuks L, Shafat I, et al. Heparanase: one molecule with multiple functions in cancer progression. Connect Tissue Res. 2008; 49(3):207-10. Epub 2008/07/29. doi: 795328198 [pii] doi: 10.1080/03008200802143281 PMID: 18661344.
12. Chen L, Sanderson RD. Heparanase regulates levels of syndecan-1 in the nucleus. PLoS One. 2009; 4 (3):e4947. Epub 2009/03/24. doi: 10.1371/journal.pone.0004947 PMID: 19305494; PubMed Central PMCID: PMC2654539.
13. Buchs AE, Zehavi S, Sher O, Yeheskely E, Muggia-Sulam M, Sherman Y, et al. Heparanase, galectin-3, and tissue factor mRNA are expressed in benign neoplasms of the thyroid. Endocrine. 2003; 22 (2):81-4. Epub 2003/12/11. doi: ENDO:22:2:81 [pii] doi: 10.1385/ENDO:22:2:81 PMID: 14665710.
14. Xu X, Quiros RM, Maxhimer JB, Jiang P, Marcinek R, Ain KB, et al. Inverse correlation between heparan sulfate composition and heparanase-1 gene expression in thyroid papillary carcinomas: a potential role in tumor metastasis. Clin Cancer Res. 2003; 9(16 Pt 1):5968-79. Epub 2003/12/17. PMID: 14676122.
15. McKenzie E, Tyson K, Stamps A, Smith P, Turner P, Barry R, et al. Cloning and expression profiling of Hpa2, a novel mammalian heparanase family member. Biochem Biophys Res Commun. 2000; 276 (3):1170-7. Epub 2000/10/12. doi: 10.1006/bbrc.2000.3586 S0006-291X(00)93586-1 [pii]. PMID: 11027606.
16. Dempsey LA, Brunn GJ, Platt JL. Heparanase, a potential regulator of cell-matrix interactions. Trends Biochem Sci. 2000; 25(8):349-51. Epub 2000/08/01. doi: S0968-0004(00)01619-4 [pii]. PMID: 10916150.
17. Nadav L, Eldor A, Yacoby-Zeevi O, Zamir E, Pecker I, Ilan N, et al. Activation, processing and trafficking of extracellular heparanase by primary human fibroblasts. Journal of cell science. 2002; 115(Pt 10):2179-87. Epub 2002/04/26. PMID: 11973358.
18. Peretti T, Waisberg J, Mader AM, de Matos LL, da Costa RB, Conceicao GM, et al. Heparanase-2, syndecan-1, and extracellular matrix remodeling in colorectal carcinoma. European journal of gastroenterology & hepatology. 2008; 20(8):756-65. doi: 10.1097/MEG.0b013e3282fc2649 PMID: 18617780.
19. Suarez ER, Paredes-Gamero EJ, Del Giglio A, Tersariol IL, Nader HB, da Pinhal MA. Heparan sulfate mediates trastuzumab effect in breast cancer cells. BMC Cancer. 2013; 13(1):444. Epub 2013/10/03. doi: 1471-2407-13-444 [pii] doi: 10.1186/1471-2407-13-444 PMID: 24083474.
20. Rodrigues LM, Oliveira LZ, Pinhal MA. Expression of heparanase isoforms in intervertebral discs classified according to Pfirrmann grading system for disc degeneration. Spine (Phila Pa 1976). 2013; 38 (13):1112-8. Epub 2013/02/02. doi: 10.1097/BRS.0b013e3182894cf4 PMID: 23370684.
21. Behzad F, Brenchley PE. A multiwell format assay for heparanase. Anal Biochem. 2003; 320(2):207-13. Epub 2003/08/21. doi: S0003269703003580 [pii]. PMID: 12927826.
22. Boucas RI, Trindade ES, Tersariol IL, Dietrich CP, Nader HB. Development of an enzyme-linked immunosorbent assay (ELISA)-like fluorescence assay to investigate the interactions of glycosaminoglycans to cells. Anal Chim Acta. 2008; 618(2):218-26. Epub 2008/06/03. doi: S0003-2670(08)00808-8 [pii] doi: 10.1016/j.aca.2008.04.059 PMID: 18513543.
23. Trindade ES, Oliver C, Jamur MC, Rocha HA, Franco CR, Boucas RI, et al. The binding of heparin to the extracellular matrix of endothelial cells up-regulates the synthesis of an antithrombotic heparan sulfate proteoglycan. J Cell Physiol. 2008; 217(2):328-37. Epub 2008/06/11. doi: 10.1002/jcp.21504 PMID: 18543288.
24. Gingis-Velitski S, Zetser A, Kaplan V, Ben-Zaken O, Cohen E, Levy-Adam F, et al. Heparanase uptake is mediated by cell membrane heparan sulfate proteoglycans. J Biol Chem. 2004; 279(42):44084-92. Epub 2004/08/05. doi: 10.1074/jbc.M402131200 M402131200 [pii]. PMID: 15292202.
25. Levy-Adam F, Feld S, Cohen-Kaplan V, Shteingauz A, Gross M, Arvatz G, et al. Heparanase 2 interacts with heparan sulfate with high affinity and inhibits heparanase activity. J Biol Chem. 2010; 285 (36):28010-9. Epub 2010/06/26. doi: M110.116384 [pii] doi: 10.1074/jbc.M110.116384 PMID: 20576607; PubMed Central PMCID: PMC2934666.
26. Linke M, Herzog V, Brix K. Trafficking of lysosomal cathepsin B-green fluorescent protein to the surface of thyroid epithelial cells involves the endosomal/lysosomal compartment. Journal of cell science. 2002; 115(Pt 24):4877-89. PMID: 12432075.
27. Zetser A, Levy-Adam F, Kaplan V, Gingis-Velitski S, Bashenko Y, Schubert S, et al. Processing and activation of latent heparanase occurs in lysosomes. Journal of cell science. 2004; 117(Pt 11):2249-58. Epub 2004/05/06. doi: 10.1242/jcs.01068 117/11/2249 [pii]. PMID: 15126626.
28. Jiang P, Kumar A, Parrillo JE, Dempsey LA, Platt JL, Prinz RA, et al. Cloning and characterization of the human heparanase-1 (HPR1) gene promoter: role of GA-binding protein and Sp1 in regulating HPR1 basal promoter activity. J Biol Chem. 2002; 277(11):8989-98. Epub 2002/01/10. doi: 10.1074/jbc.M105682200 M105682200 [pii]. PMID: 11779847.
29. Lu S, Huang M, Kobayashi Y, Komiyama A, Li X, Katoh R, et al. Alterations of basement membrane in di-isopropanolnitrosamine-induced carcinogenesis of the rat thyroid gland: an immunohistochemical study. Virchows Arch. 2000; 436(6):595-601. Epub 2000/08/05. PMID: 10917175.
30. Conejo JR, Kleeff J, Koliopanos A, Matsuda K, Zhu ZW, Goecke H, et al. Syndecan-1 expression is upregulated in pancreatic but not in other gastrointestinal cancers. Int J Cancer. 2000; 88(1):12-20. Epub 2000/08/30. doi: 10.1002/1097-0215(20001001)88:1<12::AID-IJC3>3.0.CO;2-T [pii]. PMID: 10962434.
31. Kleeff J, Ishiwata T, Kumbasar A, Friess H, Buchler MW, Lander AD, et al. The cell-surface heparan sulfate proteoglycan glypican-1 regulates growth factor action in pancreatic carcinoma cells and is overexpressed in human pancreatic cancer. J Clin Invest. 1998; 102(9):1662-73. Epub 1998/11/05. doi: 10.1172/JCI4105 PMID: 9802880; PubMed Central PMCID: PMC509114.
32. Thompson CA, Purushothaman A, Ramani VC, Vlodavsky I, Sanderson RD. Heparanase regulates secretion, composition, and function of tumor cell-derived exosomes. J Biol Chem. 2013; 288 (14):10093-9. Epub 2013/02/23. doi: 10.1074/jbc.C112.444562 C112.444562 [pii]. PMID: 23430739; PubMed Central PMCID: PMC3617250.
33. Bologna-Molina R, Gonzalez-Gonzalez R, Mosqueda-Taylor A, Molina-Frechero N, Damian-Matsumura P, Dominguez-Malagon H. Expression of syndecan-1 in papillary carcinoma of the thyroid with extracapsular invasion. Arch Med Res. 2010; 41(1):33-7. Epub 2010/05/01. doi: S0188-4409(09) 00211-2 [pii] doi: 10.1016/j.arcmed.2009.11.004 PMID: 20430252.
34. Yamanaka K, Ito Y, Okuyama N, Noda K, Matsumoto H, Yoshida H, et al. Immunohistochemical study of glypican 3 in thyroid cancer. Oncology. 2007; 73(5-6):389-94. Epub 2008/05/31. doi: 000136159 [pii] doi: 10.1159/000136159 PMID: 18511877.
35. Mitselou A, Ioachim E, Peschos D, Charalabopoulos K, Michael M, Agnantis NJ, et al. E-cadherin adhesion molecule and syndecan-1 expression in various thyroid pathologies. Exp Oncol. 2007; 29(1):54-60. Epub 2007/04/14. doi: 30/599 [pii]. PMID: 17431390.
36. Ito Y, Yoshida H, Nakano K, Takamura Y, Miya A, Kobayashi K, et al. Syndecan-1 expression in thyroid carcinoma: stromal expression followed by epithelial expression is significantly correlated with dedifferentiation. Histopathology. 2003; 43(2):157-64. Epub 2003/07/25. doi: 1656 [pii]. PMID: 12877731.
37. Arvatz G, Shafat I, Levy-Adam F, Ilan N, Vlodavsky I. The heparanase system and tumor metastasis: is heparanase the seed and soil? Cancer Metastasis Rev. 2011; 30(2):253-68. Epub 2011/02/11. doi: 10.1007/s10555-011-9288-x PMID: 21308479.
38. Theodoro TR, de Matos LL, Sant Anna AV, Fonseca FL, Semedo P, Martins LC, et al. Heparanase expression in circulating lymphocytes of breast cancer patients depends on the presence of the primary tumor and/or systemic metastasis. Neoplasia. 2007; 9(6):504-10. Epub 2007/07/03. PMID: 17603633; PubMed Central PMCID: PMC1899258.
39. Ben Arush MW, Shafat I, Ben Barak A, Shalom RB, Vlodavsky I, Ilan N. Plasma heparanase as a significant marker of treatment response in children with Hodgkin lymphoma: pilot study. Pediatr Hematol Oncol. 2009; 26(4):157-64. Epub 2009/05/14. doi: 911106651 [pii] doi: 10.1080/08880010902754917 PMID: 19437318.
40. Zhang W, Yang HC, Wang Q, Yang ZJ, Chen H, Wang SM, et al. Clinical value of combined detection of serum matrix metalloproteinase-9, heparanase, and cathepsin for determining ovarian cancer invasion and metastasis. Anticancer Res. 2011; 31(10):3423-8. Epub 2011/10/04. doi: 31/10/3423 [pii]. PMID: 21965756.
41. Marques RM, Focchi GR, Theodoro TR, Castelo A, Pinhal MA, Nicolau SM. The immunoexpression of heparanase 2 in normal epithelium, intraepithelial, and invasive squamous neoplasia of the cervix. J Low Genit Tract Dis. 2012; 16(3):256-62. Epub 2012/03/29. doi: 10.1097/LGT.0b013e3182422c69 PMID: 22453758.
42. de Moura JP Jr, Nicolau SM, Stavale JN, da Silva Pinhal MA, de Matos LL, Baracat EC, et al. Heparanase-2 expression in normal ovarian epithelium and in benign and malignant ovarian tumors. Int J Gynecol Cancer. 2009; 19(9):1494-500. Epub 2009/12/04. doi: 10.1111/IGC.0b013e3181a834a2 00009577-200912000-00006 [pii]. PMID: 19955924.
43. Zhang X, Xu S, Tan Q, Liu L. High expression of heparanase-2 is an independent prognostic parameter for favorable survival in gastric cancer patients. Cancer Epidemiol. 2013. Epub 2013/10/22. doi: S1877-7821(13)00154-9 [pii] doi: 10.1016/j.canep.2013.09.012 PMID: 24139593.
44. Eszlinger M, Paschke R. Molecular fine-needle aspiration biopsy diagnosis of thyroid nodules by tumor specific mutations and gene expression patterns. Mol Cell Endocrinol. 2010; 322(1-2):29-37. Epub 2010/01/20. doi: S0303-7207(10)00012-2 [pii] doi: 10.1016/j.mce.2010.01.010 PMID: 20083161.
45. Alexander EK, Kennedy GC, Baloch ZW, Cibas ES, Chudova D, Diggans J, et al. Preoperative Diagnosis of Benign Thyroid Nodules with Indeterminate Cytology. N Engl J Med. 2012. Epub 2012/06/27. doi: 10.1056/NEJMoa1203208 PMID: 22731672.
46. Ferraz C, Eszlinger M, Paschke R. Current state and future perspective of molecular diagnosis of fineneedle aspiration biopsy of thyroid nodules. The Journal of clinical endocrinology and metabolism. 2011; 96(7):2016-26. Epub 2011/05/20. doi: 10.1210/jc.2010-2567 PMID: 21593119.